Back to News
Market Impact: 0.5

Thursday’s big stock stories: What’s likely to move the market in the next trading session

KOPEPGEMMMUALNFLXXHBJCIBLDBLDRDFHWMSHDLOWMPAAPLSRPTPZZAWENCAKE
Corporate EarningsCompany FundamentalsMarket Technicals & FlowsAnalyst InsightsHealthcare & BiotechHousing & Real EstateCommodities & Raw Materials
Thursday’s big stock stories: What’s likely to move the market in the next trading session

United Airlines reported mixed Q2 results, beating EPS but missing revenue, with domestic passenger revenue per seat mile down 7% year-over-year, leading to a slight after-hours dip despite a 12% monthly gain. GE Aerospace continues its robust performance, up 46% in three months, ahead of its highly anticipated Thursday earnings, alongside upcoming reports from PepsiCo and Netflix. Separately, MP Materials experienced a 4%+ after-hours decline despite a 95% five-day surge driven by recent Apple and DoD deals, while Sarepta Therapeutics soared over 30% after hours following news of workforce reductions and a black-box warning for its Elevidys drug. Investors also await homebuilder sentiment data, as the sector ETF (XHB) has fallen 20% since November.

Analysis

The market is presenting a mixed landscape with significant single-stock volatility and key sector-specific catalysts on the horizon. GE Aerospace heads into its earnings report with exceptionally strong momentum, having gained 46% over the past three months and hitting a new high, setting a high bar for performance. In contrast, United Airlines delivered a mixed report, beating on EPS but missing revenue forecasts and, more critically, revealing a 7% year-over-year decline in domestic passenger revenue per available seat mile, a potential indicator of softening domestic demand. In the materials and biotech sectors, extreme volatility is evident. MP Materials saw a pullback of over 4% after-hours following a staggering 95% gain in just five trading days, which was fueled by deals with Apple and the Department of Defense. Sarepta Therapeutics provides a counterintuitive case, soaring over 30% after hours despite announcing a black-box warning for its Elevidys drug; the market is clearly prioritizing the simultaneous news of a one-third workforce reduction as a significant positive for the company's financial health. Meanwhile, the homebuilder sector shows broad weakness, with the XHB ETF down 20% from its November high, though select names like TopBuild are outperforming, highlighting significant intra-sector divergence ahead of key sentiment data.